A. Dalhoff
- Molecular Medicine top 0.2%
- Antibiotic Resistance in Bacteria 49
- Pharmacology top 0.5%
- Antibiotics Pharmacokinetics and Efficacy 75
-
- Antibiotic Use and Resistance 7
- Clinical Biochemistry top 2%
- Bacterial Identification and Susceptibility Testing 7
- Epidemiology top 2%
- Pneumonia and Respiratory Infections 22
- Urinary Tract Infections Management 11
-
- Antimicrobial Resistance in Staphylococcus 8
-
- Epilepsy research and treatment 6
A. Dalhoff
103 papers receiving 2.9k citations
Peers
Comparison fields: 5 of 122
- Molecular Medicine 1.1k
- Pharmacology 1.6k
- Applied Microbiology and Biotechnology 134
- Clinical Biochemistry 251
- Epidemiology 1.1k
Countries citing papers authored by A. Dalhoff
This map shows the geographic impact of A. Dalhoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Dalhoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Dalhoff more than expected).
Fields of papers citing papers by A. Dalhoff
This network shows the impact of papers produced by A. Dalhoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Dalhoff. The network helps show where A. Dalhoff may publish in the future.
Co-authorship network
The 25 scholars most cited alongside A. Dalhoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 7 | |
| 2 | 2010 | 43 | |
| 3 | Pharmacodynamics of moxifloxacin compared with piperacillin/tazobactam, ciprofloxacin, mezlocillin, metronidazole, and ciprofloxacin-metronidazole or -mezlocillin in mono or mixed infections of E.coli, E. Faecalis and B. fragilis in an in vitro pharmacodynamic model. | 2009 | 0 |
| 4 | Comparative Inhibitory and Bactericidal Activities of Finafloxacin (FIN) and Ciprofloxacin (CIP) against Gram-Negative and Gram-Positive UTI-pathogens Under Physiological Conditions and at Varying pH-values | 2008 | 2 |
| 5 | 2005 | 147 | |
| 6 | 2005 | 8 | |
| 7 | 2005 | 28 | |
| 8 | 2003 | 32 | |
| 9 | 2003 | 113 | |
| 10 | No evidence of active metabolites of faropenem | 2001 | 1 |
| 11 | 1999 | 29 | |
| 12 | 1995 | 8 | |
| 13 | 1995 | 12 | |
| 14 | 1990 | 32 | |
| 15 | 1988 | 6 | |
| 16 | 1988 | 4 | |
| 17 | 1985 | 56 | |
| 18 | 1982 | 4 | |
| 19 | 1982 | 3 | |
| 20 | [Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration (author's transl)]. | 1981 | 14 |
About A. Dalhoff
A. Dalhoff is a scholar working on Molecular Medicine, Pharmacology and Applied Microbiology and Biotechnology, having authored 108 papers that have together received 3.0k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (75 papers), Antibiotic Resistance in Bacteria (49 papers), Pneumonia and Respiratory Infections (22 papers), Urinary Tract Infections Management (11 papers), Antimicrobial Resistance in Staphylococcus (8 papers), Antibiotic Use and Resistance (7 papers), Bacterial Identification and Susceptibility Testing (7 papers) and Epilepsy research and treatment (6 papers). The work is most often cited by research in Molecular Medicine (1.1k citations), Pharmacology (1.6k citations) and Applied Microbiology and Biotechnology (134 citations). A. Dalhoff has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Itamar Shalit, Dagmar Kubitza, Franz‐Josef Schmitz, Rainer Endermann, Uwe Petersen, Sabine Schubert, W. Weidner, U. Ullmann, R. Rohwedder and Tom Bergan. Their work appears in journals such as Infection, Antimicrobial Agents and Chemotherapy, Chemotherapy, European Journal of Clinical Microbiology & Infectious Diseases and Journal of Antimicrobial Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.